MEDI4736 alone and in diff. combinations

Trials for Anti-PD-1 or anti-PD-L1 antibodies with participating ASPS patients
Post Reply
Olga
Admin
Posts: 2349
Joined: Mon Jun 26, 2006 11:46 pm
Location: Vancouver, Canada

MEDI4736 alone and in diff. combinations

Post by Olga »

Few ASPS patients are currently participating in the trials of MEDI4736 or its combination with some other drugs ( anti-PD-1 or anti-PD-L1 antibody).

search at the https://www.clinicaltrials.gov using the number
in Canada:

NCT02261220 A Phase 1 Study of MEDI4736 in Combination With Tremelimumab
NCT01693562 A Phase 1/2 Study to Evaluate MEDI4736

in US:

NCT02301130 Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab
but check on the clinicaltrials.gov for other trials with MEDI4736 that might be open in your area.

There are the early signs of this drug activity in ASPS so it is very reasonable to seek the participation in this group of trials if you have no other options. If you are on a trial, keep on mind that they only scan what they need for the trial and the rest of the body is your responsibility to watch for. Rachel answers to our numerous questions here:
http://www.cureasps.org/forum/viewtopic.php?f=70&t=1104
Olga
Post Reply

Return to “Immune checkpoint inhibitors (ICI)”